LONGITUDINAL EVALUATION OF SERUM ANDROGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE-CANCER

被引:92
作者
CARTER, HB
PEARSON, JD
METTER, EJ
CHAN, DW
ANDRES, R
FOZARD, JL
ROSNER, W
WALSH, PC
机构
[1] JOHNS HOPKINS UNIV HOSP, SCH MED, JAMES BUCHANAN BRADY UROL INST, DEPT LAB MED, BALTIMORE, MD 21287 USA
[2] NIA, GERONTOL RES CTR, BALTIMORE, MD 21224 USA
[3] ROOSEVELT HOSP, DIV ENDOCRINOL, NEW YORK, NY USA
关键词
HORMONES; ANDROGENS; PROSTATE CANCER;
D O I
10.1002/pros.2990270106
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Androgens are thought to play a role in the pathogenesis of prostate cancer. We evaluated androgen levels in 3 age-matched groups of men who were part of the Baltimore Longitudinal Study of Aging: 1) 16 men with no prostatic disease by urologic history and exam (control group); 2) 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and 3) 20 men with a histologic diagnosis of prostate cancer (16 with local/regional cancer, and 4 with metastatic cancer). Luteinizing hormone (LH), total testosterone (T), and free T were measured on stored AM sera by radioimmunoassay (RIA). Free T was also calculated from the measured concentrations of total T and sex hormone binding globulin (SHBG). The median number of repeated sex steroid measurements ranged from 6-9 over a period from 7-25 years prior to the diagnosis of prostate disease. There were no significant differences in age-adjusted LH, total T, SHBG, or calculated free T levels among the groups at 0-5, 5-10, and 10-15 years before diagnosis. These data suggest that there are no measurable differences in serum testosterone levels among men who are destined to develop prostate cancer and those without the disease. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:25 / 31
页数:7
相关论文
共 19 条
  • [1] BARRETTCONNOR E, 1990, CANCER RES, V50, P169
  • [2] EPIDEMIOLOGIC EVIDENCE REGARDING PREDISPOSING FACTORS TO PROSTATE-CANCER
    CARTER, BS
    CARTER, HB
    ISAACS, JT
    [J]. PROSTATE, 1990, 16 (03) : 187 - 197
  • [3] LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE
    CARTER, HB
    PEARSON, JD
    METTER, J
    BRANT, LJ
    CHAN, DW
    ANDRES, R
    FOZARD, JL
    WALSH, PC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16): : 2215 - 2220
  • [4] DEJONG FH, 1991, CANCER RES, V51, P3445
  • [5] GORMLEY GJ, 1992, J CELL BIOCHEM, P113
  • [6] CUMULATIVE PREVALENCE OF PROSTATISM MATCHES THE AUTOPSY PREVALENCE OF BENIGN PROSTATIC HYPERPLASIA
    GUESS, HA
    ARRIGHI, HM
    METTER, EJ
    FOZARD, JL
    [J]. PROSTATE, 1990, 17 (03) : 241 - 246
  • [7] HENDERSON BE, 1982, CANCER RES, V42, P3232
  • [8] HSING AW, 1993, CANCER EPIDEM BIOMAR, V2, P27
  • [9] RADIOIMMUNOASSAY FOR HUMAN TESTOSTERONE-ESTRADIOL-BINDING GLOBULIN
    KHAN, MS
    EWEN, E
    ROSNER, W
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1982, 54 (04) : 705 - 710
  • [10] NOBLE RL, 1977, CANCER RES, V37, P1929